ADHD medications: Of all available drugs, methylphenidate should be first option for short-term treatment in children
Dr. David Lowemann Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering
Study includes 133 double-blind randomized controlled trials with data from more than 14,000 children and adolescents and 10,000 adults.
